Celltrion Secures EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra®
Celltrion Secures EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra® Celltrion has announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a biosimilar referencing RoActemra®…
QIAGEN Files Legal Action to Protect QuantiFERON IP in TB Testing
QIAGEN Takes Legal Action to Defend QuantiFERON Intellectual Property and Protect Innovations in Latent Tuberculosis Testing QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has filed a patent infringement complaint…
SmithRx Adds Stelara Biosimilars, Projecting $14.5M Savings
SmithRx Adds Stelara Biosimilars, Projecting $14.5M Savings SmithRx, a transparent and fully pass-through modern pharmacy benefits manager (PBM), has announced a significant expansion of its Connect 360 Autoimmune Program. This…
Demetra Holding Acquires Majority Stake in GetSet Surgical, Expanding Spine Portfolio
Demetra Holding Acquires Majority Stake in GetSet Surgical, Expanding Spine Portfolio Demetra Holding, a pioneering and independent international medical device company specializing in anti-infective cements, spacers, and biomaterials for orthopedic…
Wedgewood Names Jessica Knopp-Gwynne Chief Revenue Officer to Lead Strategic Growth
Wedgewood Names Jessica Knopp-Gwynne Chief Revenue Officer to Lead Strategic Growth Wedgewood, the nation’s largest provider of compounded veterinary medications and pharmacy solutions, has appointed Jessica Knopp-Gwynne as Chief Revenue…
Incyte to Present Latest Dermatology Portfolio Data at 2025 AAD Annual Meeting
Incyte (Nasdaq: INCY) has announced its participation in the 2025 American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 7–11, 2025, in Orlando, where the company will present multiple…
Arrowhead Pharmaceuticals Launches FCS Patient Resources on Rare Disease Day
Arrowhead Pharmaceuticals Launches FCS Patient Resources on Rare Disease Day Arrowhead Pharmaceuticals Expands “We’ll Get There Soon” Campaign with New Resources for Familial Chylomicronemia Syndrome on Rare Disease Day Arrowhead…
Sarepta Therapeutics Opens Applications for 8th Annual Route 79 Duchenne Scholarship Program
Sarepta Therapeutics Opens Applications for 8th Annual Route 79 Duchenne Scholarship Program Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, has officially opened applications…
CHMP Recommends EU Approval of ENHERTU® for HER2 Low/Ultralow Metastatic Breast Cancer
CHMP Recommends EU Approval of ENHERTU® for HER2 Low/Ultralow Metastatic Breast Cancer Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have achieved a significant milestone with the recommendation for approval…
Seismic Therapeutic Presents Preclinical Data on S-8484 for Allergic Diseases
Seismic Therapeutic Presents Preclinical Data on S-8484 for Allergic Diseases Seismic Therapeutic, Inc., a pioneering machine learning immunology company, has announced the presentation of preclinical data for its novel immunoglobulin…
BridgeBio Oncology and Helix Acquisition Announce Merger to Advance RAS & PI3Kα Therapies
BridgeBio Oncology and Helix Acquisition Announce Merger to Advance RAS & PI3Kα Therapies BridgeBio Oncology Therapeutics (BBOT), a clinical-stage biopharmaceutical company focused on developing next-generation small molecule therapies targeting RAS…
Astria Begins Phase 3 ALPHA-ORBIT Trial of Navenibart for Hereditary Angioedema
Astria Begins Phase 3 ALPHA-ORBIT Trial of Navenibart for Hereditary Angioedema Astria Therapeutics, Inc. (Nasdaq: ATXS), a leading biopharmaceutical company dedicated to developing innovative therapies for allergic and immunological diseases,…